http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019094528-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c0982b0f02b1ed6d20a315370a3a3a |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6081 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6037 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-643 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D489-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385 |
filingDate | 2018-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f662abbde6a0fc990d20e85c39e34b64 |
publicationDate | 2019-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2019094528-A1 |
titleOfInvention | An improved heroin vaccine |
abstract | An improved heroin conjugate vaccine is detailed; to accomplish this task the systematic exploration of twenty vaccine formulations with varying combinations of carrier proteins and adjuvants were undertaken. In regard to adjuvants, a Toll-like receptor 9 (TLR9) agonist and a TLR3 agonist in the presence of alum were explored. The vaccine formulations containing TLR3 or TLR9 agonist alone-elicited strong anti-heroin antibody titers and blockade of heroin-induced antinociception when formulated with alum; however, a combination of TLR3 and 9 adjuvants did not result in improved efficacy. Investigation of stability of the two lead formulations revealed that the TLR9 but not the TLR3 formulation was stable when stored over 30 days. Furthermore, mice immunized with the TLR9 + alum heroin vaccine gained significant protection from lethal heroin doses, suggesting that this vaccine formulation is suitable for mitigating the lethal effects of heroin, even following long-term storage at room temperature. |
priorityDate | 2017-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 111.